{"id":"W3185777435","doi":"10.1158/1078-0432.ccr-21-0310","title":"Niraparib for Advanced Breast Cancer with Germline <i>BRCA1</i> and <i>BRCA2</i> Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study","year":2021,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kelowna General Hospital; Institute of Cancer Research","funders":"Daiichi Sankyo Europe; National Cancer Institute; Genentech; Eisai; Cancer Research UK; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; National Cancer Research Institute; GlaxoSmithKline; Celgene; Amgen; University of Texas MD Anderson Cancer Center; Pfizer; MacroGenics; Cancer Research Institute","keywords":"Breast cancer; Oncology; Medicine; Germline; Internal medicine; Cancer; Germline mutation; Mutation; Genetics; Biology; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005018974,0.001007268,0.002310129,0.000411835,0.0009967473,0.0003787512,0.001026802,0.001233853,0.004486023],"category_scores_gemma":[0.0009488176,0.0006970374,0.0005820193,0.001514628,0.002766229,0.0002674471,0.0004186894,0.00824138,0.00007345202],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001010805,"about_ca_system_score_gemma":0.005611092,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001188296,"about_ca_topic_score_gemma":0.001486241,"domain_scores_codex":[0.9878877,0.001884184,0.002212564,0.002818254,0.003256051,0.001941266],"domain_scores_gemma":[0.9853313,0.006726349,0.0007651956,0.002410969,0.004152175,0.0006139982],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.006141113,0.001057964,0.01046613,0.001164194,0.002016424,0.0005528374,0.0005049639,0.0000477161,0.0001724497,0.00001571961,0.9532294,0.02463105],"study_design_scores_gemma":[0.01988268,0.003528475,0.008949834,0.002615075,0.0009379602,0.0002029493,0.0008449562,0.00008322529,0.0002461731,0.0003591127,0.9613668,0.0009828062],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.04881354,0.02720599,0.0001748587,0.9030826,0.001848428,0.01358966,0.003848979,0.0002580036,0.001177956],"genre_scores_gemma":[0.04480616,0.02945151,0.0009259933,0.7840386,0.04498702,0.04200466,0.002290016,0.001234756,0.05026131],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.119044,"threshold_uncertainty_score":0.9999477,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2235213596073076,"score_gpt":0.525599806114159,"score_spread":0.3020784465068514,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}